2025北交所万里行 | 丹娜生物董事长周泽奇：以持续创新攻坚真菌诊断难题

Core Insights - The chairman of Dana Biotech, Zhou Zeqi, emphasizes the importance of long-term investment in core technology for sustainable development in the biopharmaceutical industry [2][3] - Dana Biotech, founded in 2014, has become a leader in early diagnosis of fungal diseases in China and is set to be the first IVD company listed on the Beijing Stock Exchange [2][3] - The company has developed a "5G+ Joint Detection Scheme" to enhance the precision of diagnosing various pathogenic infections [2][5] Company Development - Zhou Zeqi returned to China in 2008 to contribute to the biopharmaceutical sector and identified a significant gap in the diagnosis of pathogenic microorganisms, particularly fungal diseases [3] - The company’s first core product, derived from the horseshoe crab's blood, allows for rapid differentiation between fungal and bacterial infections, significantly improving diagnostic speed and accuracy [4][6] - The market for invasive fungal disease diagnostic reagents in China is projected to grow from 240 million yuan in 2018 to 3.03 billion yuan by 2030, with a compound annual growth rate of 23.5% [4] Innovation and R&D - Dana Biotech has obtained 91 domestic and international patents, including 48 invention patents, and has developed a diverse product matrix including antigen-antibody tests and molecular diagnostics [6][7] - The company invests over 30 million yuan annually in R&D, accounting for more than 10% of total revenue, supporting the development of six core technology platforms [6][7] - The company has developed over 70 new products through a clinical validation process that emphasizes evidence-based medicine [7] Future Prospects - The funds raised from the upcoming IPO will be used for the construction of a new headquarters and further R&D, focusing on invasive fungal infections and AI applications in diagnostics [8][9] - AI technology is expected to enhance diagnostic efficiency and accuracy, providing multidimensional diagnostic results to assist physicians [8][9] - The company aims to establish itself as a leader in the fungal diagnostics industry, aspiring to set international standards [9]